Literature DB >> 16280668

eIF4E as a marker for cervical neoplasia.

Janice Matthews-Greer1, Gloria Caldito, Arrigo de Benedetti, Guillermo A Herrera, Hugo Dominguez-Malagon, José Chanona-Vilchis, Elba A Turbat-Herrera.   

Abstract

Eukaryotic translation initiation factor 4E (eIF4E) is upregulated in cancers of the breast and head and neck. The authors have shown that eIF4E is increased in cervical neoplasia and that eIF4E upregulates human papillomavirus (HPV) oncoprotein E7. The aim of this study was to quantitate eIF4E in tissues representing a wide range of cervical pathology. The potential correlation between dysplastic grade or tumor stage with eIF4E upregulation and/or HPV genotype was analyzed for 10 normal, 27 cancer, and 37 dysplasia cases. A progressive increase in eIF4E staining intensity was found with increasing cervical pathology (P < 0.0001). No difference was seen in eIF4E stain intensity by either tumor type--squamous cell cancer (n = 18), adenocarcinoma (n = 4), or other types of cancer (n = 5) (P = 0.97)--or by tumor grade--II (n = 5) versus III (n = 7). Likewise, neither an HPV typing result of HPV 16 (n = 10) versus non-HPV 16 (n = 4) nor single HPV infection (n = 11) versus dual HPV infection (n = 3) significantly altered the eIF4E stain results (P = 0.86 and 0.97, respectively). These results indicate that eIF4E stain intensity may be useful as a marker for cervical neoplasia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16280668     DOI: 10.1097/01.pai.0000170625.98446.3e

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  13 in total

Review 1.  A review of the association between osteosarcoma metastasis and protein translation.

Authors:  T S Osborne; C Khanna
Journal:  J Comp Pathol       Date:  2012-01-31       Impact factor: 1.311

Review 2.  Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Authors:  Katherine L B Borden; Biljana Culjkovic-Kraljacic
Journal:  Leuk Lymphoma       Date:  2010-10

3.  Evaluation of eIF4E expression in an osteosarcoma-specific tissue microarray.

Authors:  Tanasa S Osborne; Ling Ren; John H Healey; Lauren Q Shapiro; Alexander J Chou; Richard G Gorlick; Stephen M Hewitt; Chand Khanna
Journal:  J Pediatr Hematol Oncol       Date:  2011-10       Impact factor: 1.289

Review 4.  Genome-wide analysis of microRNA and mRNA expression signatures in cancer.

Authors:  Ming-hui Li; Sheng-bo Fu; Hua-sheng Xiao
Journal:  Acta Pharmacol Sin       Date:  2015-08-24       Impact factor: 6.150

5.  The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival.

Authors:  Matthew J Wheater; Peter Wm Johnson; Jeremy P Blaydes
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

Review 6.  The biological and therapeutic relevance of mRNA translation in cancer.

Authors:  Sarah P Blagden; Anne E Willis
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

Review 7.  The oncogene eIF4E: using biochemical insights to target cancer.

Authors:  Martin Carroll; Katherine L B Borden
Journal:  J Interferon Cytokine Res       Date:  2013-03-08       Impact factor: 2.607

8.  mTOR downstream effectors, 4EBP1 and eIF4E, are overexpressed and associated with HPV status in precancerous lesions and carcinomas of the uterine cervix.

Authors:  Aristidis Asimomytis; Maria Karanikou; Alexander Rodolakis; Anna Vaiopoulou; Paraskevi Tsetsa; George Creatsas; Theodoros Stefos; Aristidis Antsaklis; Efstratios Patsouris; George Z Rassidakis
Journal:  Oncol Lett       Date:  2016-08-29       Impact factor: 2.967

9.  Expression analysis and clinical significance of eIF4E, VEGF-C, E-cadherin and MMP-2 in colorectal adenocarcinoma.

Authors:  Minna Gao; Xiong Zhang; Dan Li; Ping He; Wenguang Tian; Bo Zeng
Journal:  Oncotarget       Date:  2016-12-20

10.  Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.

Authors:  Biljana Culjkovic; Katherine L Borden
Journal:  J Oncol       Date:  2009-12-13       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.